CureVac’s Final Chapter: Nasdaq Exit Confirmed Following BioNTech Acquisition

The independent journey of CureVac as a publicly traded company has reached its conclusion. The Tübingen-based vaccine developer is now on the verge of a Nasdaq delisting, a direct outcome of its successful acquisition by rival BioNTech. For remaining shareholders, a final countdown has begun, marking the end of the firm’s autonomy and paving the way for the compulsory buyout of minority interests.

A Controlling Stake Secured

BioNTech has cleared a critical milestone in the takeover process. Following the expiration of an additional acceptance period, the Mainz-based company now commands approximately 86.75 percent of CureVac’s outstanding shares. This figure comfortably surpasses the 80 percent minimum threshold required to proceed with the transaction.

Valued at roughly $1.25 billion in an all-stock deal, the biotechnology firm is being consolidated under new ownership. CureVac, once a competitor in the mRNA vaccine race, will effectively operate as a subsidiary of its larger peer, forfeiting its standalone status.

Countdown to a Mandatory Buyout

Investors still holding CureVac shares face a strictly defined timeline. BioNTech has formally declared its intention to execute a “squeeze-out” procedure in January 2026. This legal mechanism will force out the remaining minority shareholders, typically in exchange for a predetermined cash compensation.

Should investors sell immediately? Or is it worth buying CureVac?

The immediate consequence is the termination of the company’s listing on the Nasdaq Global Market. Consequently, market participants are now trading a security with a fixed expiration date. This reality has recently been reflected in the share price, which exhibited significant volatility and fell by over 12 percent at times as it adjusted to the exchange ratio and the impending delisting.

Financials Fade into the Background

Recent fundamental data, including third-quarter results released in late November, depict an organization in transition. CureVac reported a net profit of €273.2 million, yet this was primarily driven by one-off effects—specifically a $370 million settlement payment from a patent dispute with Pfizer and BioNTech. The company hands over a robust balance sheet to its new parent, with a cash position of €416.1 million as of September 30, 2025.

However, these financial metrics are rapidly becoming historical footnotes. The operational focus has now shifted entirely toward integration into BioNTech’s framework, aiming to combine strengths in oncology and infectious disease research. The ticker symbol “CVAC” is slated to disappear from trading boards shortly after the squeeze-out is formalized in January, drawing the final curtain on CureVac’s stock market story.